Pfizer/Valneva Aim for FDA Approval of mRNA Shot for Lyme Disease
On Mar. 23, 2026, Pfizer, Inc. of New York City, NY and Valneva SE of Saint-Herblain, France announced that they would seek regulatory approval from the U.S. Food and Drug Administration (FDA) for an experimental mRNA (messenger ribonucleic acid) biologic shot against Lyme disease that they have jointly been developing since 2020. The shot, designated […]
Pfizer/BioNTech mRNA Combo Influenza and COVID Shot Efficacy Fails in Trial
Pfizer and BioNTech recently announced that a new mRNA vaccine designed to protect against both COVID-19 and influenza in a single shot faced a major setback after failing to achieve one of its primary goals in a late-stage trial. The “primary goal” missed in the late-stage trials was the ability to effectively prevent influenza B. […]
Novel mRNA Lyme Shots Could Be Released in 2025
Two novel messenger RNA (mRNA) shots for Lyme disease currently in late-stage clinical trials could hit the market as early as 2025, Moderna announced earlier this year. Also in the race to develop the first-ever mRNA product to prevent Lyme disease are Pfizer and Austria-based Valneva, which entered into a collaborative agreement in April 2020 […]